Shining a Spotlight on RNA m6A Modifications and Potential Targeted Immunotherapy in Ovarian Cancer

Objective: Ovarian cancer is one of the major gynecologic malignancies worldwide. Evidence indicates that N6-methyladenosine (m6A) modification is strongly related to cancer immunity. This review aims to demonstrate the role and function of m6A modification in ovarian cancer tumorigenesis and its potential targeted immunotherapy. Mechanism: Searching the literature for articles related to the m6A modification and ovarian cancer and immunotherapy. Conducting a comprehensive analysis and summarizing the content logically. Findings in Brief: In this review, we summarized the latest research on the function of m6A regulators in ovarian cancer tumorigenesis and targeted immunotherapy. Firstly, we found the function and underlying molecular mechanism of m6A regulators (writers, erasers and readers) in the development and progress of ovarian cancer. Then, we discovered that m6A regulators play a pivotal role in cancer immune responses and efficacy, serving as potential therapeutic targets for cancer immunotherapy. Additionally, m6A related long noncoding RNAs (lncRNAs) have a strong impact on ovarian cancer survival and immunotherapy. Finally, deeply analyzing of m6A modification and targeted genes are needed to improve the potential immunotherapy of ovarian cancer. Conclusions: m6A modification has strong potential in ovarian cancer carcinogenesis and immunotherapy.